ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
MLH1 promoter methylation in pancreatic ductal adenocarcinoma: frequent but not prognostic.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutL homolog 1 (MLH1) is a key component of the mismatch repair (MMR) pathway, and promoter methylation-mediated silencing is a well-established oncogenic mechanism in several tumor types. However, its prevalence and prognostic relevance in pancreatic ductal adenocarcinoma (PDAC) remain unclear.
methodsWe retrospectively analyzed 55 patients with PDAC diagnosed between 2012 and 2021 at a tertiary center. MLH1 promoter methylation (%) was quantified by pyrosequencing in formalin-fixed, paraffin-embedded tumor samples and classified using predefined (8%) and exploratory ROC-derived (2.6%) cut-offs. Associations with clinicopathological variables and disease-specific survival (DSS) were assessed using Cox regression models, with additional exploratory quartile-based and cubic spline analyses. External validation was performed using multi-omics data from The Cancer Genome Atlas Pancreatic Adenocarcinoma (TCGA-PAAD) cohort.
resultsMLH1 promoter methylation levels varied widely (mean 11.3%, range 2.0-42.2%) with 41.8% and 74.5% of cases classified as methylated using the predefined and exploratory cut-offs, respectively. No significant associations were observed with clinicopathological variables. In multivariable analysis, MLH1 methylation was not associated with DSS at either cut-off (HR = 1.55, 95% CI 0.85-2.85, p = 0.153; HR = 1.31, 95% CI 0.66-2.62, p = 0.442). Quartile-based and cubic spline analyses did not identify threshold-dependent or non-linear associations with DSS. In TCGA-PAAD data, neither MLH1 methylation nor gene expression correlated with overall survival, whereas low MLH1 protein expression was associated with worse outcomes.
conclusionAlthough MLH1 promoter methylation is frequent in PDAC, it was not associated with DSS. These findings suggest limited prognostic value of MLH1 promoter methylation alone and support the integration of functional and multi-layered molecular data.
Indexed as
Identifiers
42576118What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.